Why COAs Alone Don't Prove Much in the Grey-Market Peptide World

A Certificate of Analysis, or COA, can be useful—but only when it is treated as a starting point, not a guarantee. In the grey-market peptide world, COAs often create the appearance of certainty without actually proving that the vial in someone's hand is the same material that was tested.

A COA is paperwork. The product is chemistry.

The problem is simple: a COA is paperwork. The product is chemistry. Unless the paperwork can be tied to the exact lot, batch, and vial being purchased, it may only show that some sample passed some test at some time. A COA that is not tied to a lot number is closer to marketing than proof, because it does not confirm what is actually sitting in the vial now.

The conflict of interest

There is also an obvious conflict of interest. A supplier-provided COA is usually produced or supplied by the same party selling the product. That does not automatically mean the document is fake, but it does mean it should not be treated as independent proof. Even in regulated supply chains, responsible manufacturers do not simply accept supplier claims blindly. They verify materials, confirm identity, and build trust through repeated testing and documentation.

Purity is not the whole picture

For peptides, the issue gets even more specific. A peptide COA may show “99% purity by HPLC,” but purity is not the same thing as identity, potency, sterility, endotoxin status, or net peptide content. A vial can look great on a purity test and still be underfilled, mislabeled, contaminated, non-sterile, or unsuitable for its intended research protocol. Purity and content answer different questions, and a COA that only shows one number is only telling part of the story.

That is why a serious verification standard should include more than a screenshot of a COA. At minimum, researchers should look for HPLC purity, mass spectrometry identity, net peptide content, and—when sterile handling is relevant—endotoxin and sterility information. One test result cannot answer every quality question.

A COA should be a starting filter, not final proof.

Geography is not proof

This does not mean every overseas peptide is bad, or that every domestic seller is better. Geography is not proof. Testing is. The real question is not “Where did it come from?” but “Can this exact batch be independently verified?”

In the grey-market peptide world, chain of custody matters. A seller can show a legitimate-looking COA for a clean sample, a previous batch, a different lot, or a document that has been copied around. Unless the buyer can match the COA to the exact lot and verify the report directly with the testing lab, the COA may create more confidence than it deserves.

So are COAs pointless?

Not completely. A COA can be useful as a first filter. A vendor who cannot produce any lot-specific documentation should raise concern. But a COA by itself is not final proof. It is a claim that needs to be verified.

The strongest evidence comes from testing the actual product received.

The strongest evidence comes from independent testing of the actual product received. That means sending a sample from the real order to a qualified third-party lab and comparing the result against the label and the supplier's documentation. Without that step, the buyer is still mostly trusting the seller's paperwork. With that step, the buyer moves from trust to evidence.

In the grey-market peptide world, that difference matters. A COA may help start the conversation, but independent testing is what gives it weight.